CINQAIR Drug Profile

Summary for Tradename: CINQAIR

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for CINQAIR

Recent Clinical Trials for CINQAIR

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Jewish Health	Phase 2
Teva Pharmaceuticals USA	Phase 2
TEVA	Phase 2

See all CINQAIR clinical trials

Pharmacology for CINQAIR

Mechanism of Action	Interleukin-5 Antagonists
Established Pharmacologic Class	Interleukin-5 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CINQAIR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CINQAIR Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	6,056,957	2017-05-02	Company disclosures
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	RE39548	2014-06-17	Company disclosures

3) Low Certainty: US Patents for CINQAIR Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,028,940	2033-08-13	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,111,968	2032-02-15	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,195,183	2033-08-13	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,195,211	2035-06-15	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,369,114	2033-03-14	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,435,452	2035-05-29	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	10,456,381	2033-08-13	Patent claims search

International Patents for CINQAIR

Country	Patent Number	Estimated Expiration
Slovakia	160096
United Kingdom	9412230
Spain	2218546
Czech Republic	292295
New Zealand	287927
Japan	3973682
Slovakia	282625

CINQAIR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: CINQAIR

Introduction

CINQAIR (reslizumab) is a biologic drug used in the treatment of severe asthma, specifically for patients with eosinophilic asthma. To understand the market dynamics and financial trajectory of CINQAIR, it is essential to delve into the broader context of the severe asthma treatment market, the role of biologics, and the specific performance of CINQAIR.

The Severe Asthma Treatment Market

The global severe asthma treatment market is experiencing significant growth, driven by several key factors. The increasing prevalence of severe asthma, the development of novel biologic therapies, and rising awareness among patients and healthcare providers are major drivers of this growth. The market is projected to grow from $22 billion in 2023 to $36.18 billion by 2033, at a CAGR of 5.1% during this period[1].

Role of Biologics in Asthma Treatment

Biologics have revolutionized the treatment of severe asthma, offering targeted therapies that address specific patient sub-types. Drugs like CINQAIR, Nucala (mepolizumab), and benralizumab have been approved and are gaining traction in the market. These biologics are designed to reduce eosinophil counts, a key factor in eosinophilic asthma, thereby improving symptoms and reducing exacerbations[4].

CINQAIR: A Specific Biologic Therapy

CINQAIR (reslizumab) is an interleukin-5 (IL-5) antagonist that targets the IL-5 pathway, which is involved in the growth and survival of eosinophils. It is administered via intravenous infusion and is indicated for the treatment of severe asthma with an eosinophilic phenotype.

Approval and Market Impact

CINQAIR was approved by regulatory bodies in several countries, including the U.S. FDA, marking a significant milestone in the treatment of severe asthma. Its approval has contributed to the growth of the biologics segment within the respiratory market. The presence of CINQAIR and other biologics has shifted the market landscape from traditional small molecule therapies to more targeted and effective treatments[4].

Market Performance

While specific financial data for CINQAIR alone is not readily available, its performance can be inferred from the broader market trends and the performance of its parent company, Teva Pharmaceuticals. Teva has reported growth in its innovative products segment, which includes biologics like CINQAIR. For instance, Teva's revenues in 2023 increased by 6% compared to 2022, partly due to higher revenues from innovative products[2].

Competitive Landscape

The market for severe asthma biologics is competitive, with several key players including AstraZeneca, GSK, and Teva. CINQAIR competes directly with other IL-5 antagonists like Nucala and benralizumab. The competitive landscape is driven by the efficacy, safety, and convenience of these biologics, as well as their pricing and market access strategies[1].

Pricing and Access

Pricing is a critical factor in the biologics market, especially for drugs like CINQAIR that are used for chronic conditions. The cost of biologic therapies can be high, which may impact their adoption and market share. However, the value these drugs bring in terms of improved patient outcomes and reduced healthcare utilization can justify their costs. Market access strategies, including reimbursement policies and patient assistance programs, also play a significant role in the financial trajectory of these drugs[1].

Patient and Healthcare Provider Awareness

The increasing awareness among patients and healthcare providers about the benefits of biologic therapies is driving the demand for CINQAIR and similar drugs. Educational initiatives and marketing efforts by pharmaceutical companies are crucial in raising this awareness and promoting the use of these targeted therapies[1].

Financial Trajectory

Revenue Growth

The revenue growth of CINQAIR is tied to the overall growth of the severe asthma treatment market. As more patients are diagnosed and treated with biologic therapies, the revenue from these drugs is expected to increase. Teva's financial reports indicate that the company's innovative products, including CINQAIR, have contributed significantly to its revenue growth[2].

Market Share

CINQAIR's market share within the biologics segment for severe asthma is influenced by its efficacy, safety profile, and market access. While specific market share data for CINQAIR is not available, it is part of a growing segment that is expected to continue expanding as more patients are treated with biologic therapies[1].

Regional Performance

The performance of CINQAIR varies by region, with different markets having different levels of adoption and reimbursement policies. In regions like North America and Europe, where there is higher awareness and better reimbursement, CINQAIR is likely to perform better compared to other regions[1].

Key Takeaways

• Market Growth: The severe asthma treatment market is growing at a CAGR of 5.1% from 2023 to 2033, driven by the increasing prevalence of severe asthma and the development of novel biologic therapies.
• Role of Biologics: Biologics like CINQAIR are revolutionizing the treatment of severe asthma by offering targeted therapies that improve patient outcomes.
• Competitive Landscape: The market is competitive, with several key players, and CINQAIR competes directly with other IL-5 antagonists.
• Pricing and Access: Pricing and market access strategies are critical for the adoption and financial performance of CINQAIR.
• Awareness and Education: Increasing awareness among patients and healthcare providers is driving the demand for biologic therapies.

FAQs

What is CINQAIR used for?

CINQAIR (reslizumab) is used for the treatment of severe asthma with an eosinophilic phenotype.

How does CINQAIR work?

CINQAIR works by targeting the interleukin-5 (IL-5) pathway, which is involved in the growth and survival of eosinophils.

What is the market size of the severe asthma treatment market?

The global severe asthma treatment market is projected to grow from $22 billion in 2023 to $36.18 billion by 2033.

Who are the key players in the severe asthma treatment market?

Key players include AstraZeneca, GSK, and Teva Pharmaceuticals.

How is CINQAIR administered?

CINQAIR is administered via intravenous infusion.

Sources

1. Future Market Insights: Severe Asthma Treatment Market - Size, Growth, Trends & Share
2. Teva Pharmaceuticals: Teva Reports Growth in Fourth Quarter and Full Year 2023
3. JACI Global: Systematic literature review of asthma biologic self-administration
4. Pharmaceutical Executive: Global Respiratory Market “to be Worth $41.3 billion by 2023”